RxDoctor Payments Data

Frankie Stanley, MD

Psychiatry · Tupelo, MSNPI 1053625012

Payments from drug & device makers

$1,461in general payments, 2019–2025

Across 69 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
  • AbbVie$234
  • Johnson & Johnson$210
  • Supernus Pharmaceuticals, Inc.$195
  • Alkermes, Inc.$169
  • Axsome Therapeutics, Inc.$124
  • plus $172 from 5 others

What the payments were for

  • Food & beverage$1,458100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,461 in reported general payments places this provider in the 65th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$75,461
Medicare patients
79
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate21$34,692
Duloxetine Hcl80$4,247
Diazepam189$1,931
Atomoxetine Hcl27$1,859
Vilazodone Hcl19$1,691
Bupropion XlBupropion Hcl122$1,682
Zolpidem Tartrate ErZolpidem Tartrate12$1,579
Alprazolam262$1,558
Aripiprazole85$1,456
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,298
Olanzapine55$985
Clonazepam135$928
Desvenlafaxine Succinate ErDesvenlafaxine Succinate41$909
Venlafaxine Hcl ErVenlafaxine Hcl118$864
Buspirone Hcl86$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$357$34,69221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →